Timothy A. Springer net worth and biography

Timothy Springer Biography and Net Worth

Director of Assembly Biosciences

Dr. Timothy Springer is the Director of Assembly Biosciences.

What is Timothy A. Springer's net worth?: The estimated net worth of Timothy A. Springer is at least $152.27 million as of April 9th, 2025. Dr. Springer owns 4,317,276 shares of Assembly Biosciences stock worth more than $152,270,325 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Springer may own. Learn More about Timothy A. Springer's net worth.
How do I contact Timothy A. Springer?: The corporate mailing address for Dr. Springer and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on Timothy A. Springer's contact information.
Has Timothy A. Springer been buying or selling shares of Assembly Biosciences?: Timothy A. Springer has not been actively trading shares of Assembly Biosciences during the past quarter. Learn More on Timothy A. Springer's trading history.
Who are Assembly Biosciences' active insiders?: Assembly Biosciences' insider roster includes William Delaney (Insider), John McHutchison (CEO), and Timothy Springer (Director). Learn More on Assembly Biosciences' active insiders.
Are insiders buying or selling shares of Assembly Biosciences?: During the last twelve months, Assembly Biosciences insiders bought shares 1 times. They purchased a total of 3,202 shares worth more than $49,983.22. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,292 shares worth more than $12,726.20. The most recent insider tranaction occured on March, 31st when insider Jeanette M Bjorkquist sold 180 shares worth more than $1,773.00. Insiders at Assembly Biosciences own 5.3% of the company. Learn More about insider trades at Assembly Biosciences.
Information on this page was last updated on 3/31/2025.

Timothy A. Springer Insider Trading History at Assembly Biosciences

Timothy A. Springer Buying and Selling Activity at Assembly Biosciences

Assembly Biosciences Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Today's Range

Now: $35.27

$34.52

$35.82

50 Day Range

MA: $31.10

$23.32

$38.50

2 Week Range

Now: $35.27

$7.75

$39.71

Volume

45,842 shs

Average Volume

126,843 shs

Market Capitalization

$557.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14